Long-term Surival of GIST Patients ≥ 10 Years on Imatinib

European Organisation for Research and Treatment of Cancer (EORTC)

Status: Withdrawn

Conditions: GIST

Treatments: Other: No intervention

Study type: Observational

Funder types: NETWORK

Identifiers

NCT04097093

EORTC 1826-STBSG

Details and patient eligibility

About

This is a cross-sectional cohort study of metastatic GastroIntestinal Stromal Tumor (GIST) patients on imatinib for ≥ 10 years included in EORTC trial 62005-STBSG entitled "Phase 3 randomized, intergroup, international tiral assessing the clinical activity of STI-571 at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumor (GIST) expressing the KIT receptor tyrosine kinase (CD117) - NCT00685828". With this study, the aim is to identify patient characteristics, tumour characteristics, treatment factors and quality of life outcomes associated with prolonged treatment with imatinib and/or prolonged survival. This observational study will further help to put in place a questionnaire to evaluate patients quality of life with prolonged imatinib treatment, that will then be used in a prospective study.

Sex: All

Ages: 28+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Patients included in the EORTC 62005 trial: Adult patients with metastasized GIST

• Patients who have been treated with imatinib for ten years or longer

• For the identified patients who are still alive:

  1. Able to read and answer questionnaires
  2. Able to provide written informed consent

Trial design

0 participants in 1 patient group

Study 62005-STBSG patients treated with imatinib > 10 years

Treatment:

Other: No intervention